Charles "Chuck" Wilson, PhD
President & CEO, Unum Therapeutics
Chuck leads the company. Before founding Unum, Chuck led partnering for Novartis research and was responsible for all efforts in drug discovery up through clinical Phase II development. He brings deal experience in biotech and academic collaborations, product in-licensing, spin-outs, and strategic equity investing in early stage companies. Prior to Novartis, Chuck held both scientific and business management roles in biotechnology.
Partner, F-Prime Capital
Ben is a Partner at F-Prime Capital, and has worked in pharmaceuticals and life-sciences for over fifteen years, both in industry, as a consultant, and as an investor. Ben focuses on therapeutics, with a particular interest in Series A and company formation. He currently serves on the Board of Directors of Unum Therapeutics, Precision Biosciences, and Symbiomix Pharmaceuticals, and is Chairman of the Board of Dimension Therapeutics. Most recently before joining F-Prime Capital, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company. He holds a Bachelors of Arts from Harvard University.
Bruce Booth, DPhil
Partner, Atlas Ventures
Bruce is a partner at Atlas Venture and focuses on the discovery and development of novel therapeutics. Since joining in 2005, Bruce has been involved in the founding and funding of a number of innovative companies with a particular focus on forming unique, innovative, and capital efficient models for drug R&D. He is a co-founder/founding investor and currently chair of the boards of miRagen Therapeutics, Nimbus Therapeutics, Padlock Therapeutics, Quartet Medicine, and Rodin Therapeutics. He serves on the boards of Zafgen, Lysosomal Therapeutics Inc., and several other seed-stage biotech companies. Prior to joining Atlas, Bruce was an investor with Caxton Health Holdings and a consultant at McKinsey & Company, where he helped to build the Pharma R&D practice. He received a D.Phil. (PhD) from Oxford University as a Marshall Scholar and a Bachelor of Science from The Pennsylvania State University.
Liam Ratcliffe, MD, PhD
Managing Director, New York, New Leaf Venture Partners
Liam is a Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. He previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. He received his MD degree and PhD degree in immunology from the University of Cape Town and his MBA degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa. He serves on the boards of Afferent Pharmaceuticals, Karus Therapeutics, Calchan Holdings, and Neuronetics Inc. Liam also serves on various industry and university advisory boards, including the Leadership Counsel of the University of Michigan Life Sciences Institute, the Advisory Council of the Keck Graduate Institute and the Partnership fund for New York City.
Chairman of Molecular Partners, Zurich, Switzerland
Joern is a biotech executive and serial company builder. He built uniQure NV (NASDAQ:QURE), the first company in the Western world to obtain a gene therapy approval. He is Chairman of Molecular Partners AG (SWIX:MOLN), a developer of a powerful new class of small protein therapies called DARPins. Before becoming the CEO of uniQure, Joern led Evotec AG (FSE:EVTC), a company creating integrated high-value drug discovery alliances and developing a pipeline of CNS programs. During his tenure at Evotec, he successfully acquired LSE-listed Oxford Asymmetry and NASDAQ-listed Renovis Inc. In his life prior to biotech, he rose through the financial ranks in two German DAX 30 companies and was a business leader at Treuhandanstalt, the privatization agency of the former state-owned East German industry. He studied at the European Business School and Harvard Business School (AMP).